Will there be federal vaccine mandates for school children by end of 2025? | Binary | | | 7 days ago | |
Eli Lilly's AI-driven antimicrobial project gets clinical trial approval by end of 2024? | Binary | | | 6 months ago | |
First AI-developed drug candidate from Eli Lilly and OpenAI collaboration? | Categorical | | | 6 months ago | |
Eli Lilly and OpenAI publish joint research by September 30, 2024? | Binary | | | 6 months ago | |
First major milestone of Eli Lilly's AI-driven drug discovery program? | Categorical | | | 6 months ago | |
Publication venue for first joint research paper by Eli Lilly and OpenAI? | Categorical | | | 6 months ago | |
Eli Lilly announces AI-developed drug candidate by end of 2024? | Binary | | | 6 months ago | |
Will Eli Lilly and OpenAI identify a novel antimicrobial drug candidate by March 31, 2024? | Categorical | | | 6 months ago | |
How many drug-resistant bacteria strains will Eli Lilly and OpenAI target by June 30, 2024? | Categorical | | | 6 months ago | |
Will Eli Lilly's stock price increase by 10% or more by end of 2024 due to the collaboration with OpenAI? | Binary | | | 6 months ago | |
Will the FDA approve a new antimicrobial drug by Eli Lilly and OpenAI by end of 2024? | Binary | | | 6 months ago | |
How many new partnerships will Eli Lilly and OpenAI announce in the field of drug discovery by end of 2024? | Categorical | | | 6 months ago | |
Will there be a peer-reviewed study on a new antimicrobial by Eli Lilly and OpenAI by June 30, 2024? | Binary | | | 6 months ago | |
Eli Lilly announces new clinical trials for Zepbound targeting sleep apnea by end of 2024? | Binary | | | 6 months ago | |
Zepbound market share increases significantly by end of 2024? | Binary | | | 6 months ago | |
FDA approves Zepbound for sleep apnea by end of 2024? | Binary | | | 6 months ago | |
Zepbound's market approval status by end of 2024? | Categorical | | | 6 months ago | |
What will be the FDA's decision on Zepbound for sleep apnea by end of 2024? | Categorical | | | 6 months ago | |
Will ≥ 40% of OSA patients with obesity resolve symptoms with Zepbound by June 30, 2025? | Binary | | | 6 months ago | |
Will ≥ 50% of patients resolve sleep apnea symptoms with Zepbound by June 30, 2025? | Binary | | | 6 months ago | |
Will Zepbound receive FDA approval for sleep apnea by end of 2024? | Binary | | | 6 months ago | |
Zepbound sales reach $1 billion by mid-2025? | Binary | | | 6 months ago | |
Eli Lilly stock price increases by 10% by July 21, 2024? | Binary | | | 6 months ago | |
FDA approval of Zepbound for OSA by end of 2024? | Binary | | | 6 months ago | |
Top pharmaceutical company by market cap by end of 2024 | Categorical | | | 6 months ago | |
WHO warning on counterfeit weight-loss drugs by December 31, 2024? | Binary | | | 6 months ago | |
Lawsuit resolution against counterfeit sellers by end of 2024? | Binary | | | 6 months ago | |
FDA statement on counterfeit Mounjaro or Zepbound by September 30, 2024? | Binary | | | 6 months ago | |
FDA actions against counterfeit Mounjaro or Zepbound by December 31, 2024 | Categorical | | | 6 months ago | |
Will the FDA take action against fake Mounjaro and Zepbound products by end of 2024? | Binary | | | 6 months ago | |
Will Eli Lilly win the lawsuit against six entities by end of 2024? | Binary | | | 6 months ago | |
How will Eli Lilly's stock price react to the crackdown on fake medications by September 30, 2024? | Categorical | | | 6 months ago | |
How many settlements will be reached in lawsuits over fake Mounjaro and Zepbound by end of 2024? | Categorical | | | 6 months ago | |
Will Eli Lilly issue a new warning about fake GLP-1 medications by September 30, 2024? | Binary | | | 6 months ago | |
Leading Cause of Donanemab Discontinuation in First Year? | Categorical | | | 7 months ago | |
Region with Highest Donanemab Uptake in First Year? | Categorical | | | 7 months ago | |
First Competing Alzheimer's Drug Approved Post-Donanemab? | Categorical | | | 7 months ago | |
Donanemab Sales Over $1 Billion in First Year Post-Approval? | Binary | | | 7 months ago | |
FDA Full Approval for Donanemab by Year-End 2024? | Binary | | | 7 months ago | |
What will be the first-year sales figures for donanemab by December 31, 2025? | Categorical | | | 7 months ago | |
How will donanemab compare to Leqembi in market share by December 31, 2024? | Categorical | | | 7 months ago | |
What type of approval will the FDA give to donanemab by August 31, 2024? | Categorical | | | 7 months ago | |
Will Eli Lilly's stock price increase by 5% or more within 7 days of FDA decision on donanemab? | Binary | | | 7 months ago | |
Will the FDA approve donanemab by August 31, 2024? | Binary | | | 7 months ago | |
Will the FDA panel recommend approval of donanemab? | Binary | | | 7 months ago | |
What will be the general market reaction to Ashkenazi's appointment as Alphabet CFO in the first 3 months? | Categorical | | | 7 months ago | |
Which financial metric will show the most improvement after Ashkenazi's appointment as Alphabet CFO? | Categorical | | | 7 months ago | |
Will Alphabet's quarterly earnings report exceed analysts' expectations after Ashkenazi's appointment? | Binary | | | 7 months ago | |
Will Alphabet's stock price increase by 10% within 3 months of Ashkenazi's appointment? | Binary | | | 7 months ago | |
Will Anat Ashkenazi make a major financial announcement for Alphabet by end of 2024? | Binary | | | 7 months ago | |
Primary focus of Anat Ashkenazi's first major initiative as Alphabet CFO? | Categorical | | | 7 months ago | |
Successor of Anat Ashkenazi as Eli Lilly CFO? | Categorical | | | 7 months ago | |
Ruth Porat announce retirement from Alphabet by end of 2024? | Binary | | | 7 months ago | |
Eli Lilly appoint a new CFO by end of 2024? | Binary | | | 7 months ago | |
Alphabet stock price increase by 10% within 3 months of Anat Ashkenazi's tenure? | Binary | | | 7 months ago | |
Eli Lilly Market Share by End of 2026 | Categorical | | | 7 months ago | |
Construction Start of Eli Lilly's New Facility Before 2026 | Binary | | | 7 months ago | |
Clinical trial stage for Aktis Oncology’s anticancer drugs by end of 2024 | Categorical | | | 7 months ago | |
Eli Lilly acquires additional stake in Aktis Oncology in 2024? | Binary | | | 7 months ago | |
Development delay announced by Aktis Oncology or Eli Lilly in 2024? | Binary | | | 7 months ago | |
Aktis Oncology achieves first milestone payment in 2024? | Binary | | | 7 months ago | |
Total milestone payments to Aktis Oncology in 2024 | Categorical | | | 7 months ago | |
How many new anticancer radiopharmaceuticals will enter clinical trials by the end of 2025? | Categorical | | | 7 months ago | |
Will the collaboration successfully complete a phase 1 clinical trial of a new anticancer radiopharmaceutical by the end of 2025? | Binary | | | 7 months ago | |
Will Aktis Oncology and Eli Lilly terminate their collaboration by the end of 2025? | Binary | | | 7 months ago | |
Eli Lilly to expand Tirzepatide production due to high demand in China by H2 2024? | Binary | | | 7 months ago | |
Tirzepatide overtakes rival in sales in its first quarter in China? | Binary | | | 7 months ago | |
Eli Lilly begins Tirzepatide sales in China by end of 2024? | Binary | | | 7 months ago | |
New approvals for Tirzepatide's additional indications in China by 2024 | Categorical | | | 7 months ago | |
Number of Tirzepatide competitors entering China by 2024 | Categorical | | | 7 months ago | |
Market share of Tirzepatide in China by end of 2024 | Categorical | | | 7 months ago | |
How many competitors will launch similar once-weekly insulin products within 2 years after Efsitora's launch? | Categorical | | | 7 months ago | |
How many major markets outside the US will approve Efsitora by the end of 2025? | Categorical | | | 7 months ago | |
Will Eli Lilly's stock price increase within 3 months following successful Phase 3 trials announcement? | Binary | | | 7 months ago | |
Will Eli Lilly start commercial production of Efsitora within 6 months of FDA approval? | Binary | | | 7 months ago | |
Competitor's Response to Zepbound by 2024? | Binary | | | 8 months ago | |
Competitors Developing Similar Sleep Apnea Treatments by 2024 | Categorical | | | 8 months ago | |
FDA Approval of Zepbound for Sleep Apnea by 2024? | Binary | | | 8 months ago | |
Reported Side Effects of Zepbound Post-FDA Approval | Categorical | | | 8 months ago | |
Will Zepbound receive FDA approval for another indication by end of 2025? | Binary | | | 2 days ago | |
Will Zepbound receive expanded insurance coverage for sleep apnea by June 30, 2025? | Binary | | | 2 days ago | |
Will FDA approve a generic tirzepatide by end of 2025? | Binary | | | 2 days ago | |
Will Zepbound receive EMA approval by the end of 2025? | Binary | | | 2 days ago | |
Will Novo Nordisk announce a new Phase 3 trial for CagriSema by end of 2025? | Binary | | | 3 days ago | |
Will Novo Nordisk's CagriSema receive FDA approval by end of 2025? | Binary | | | 3 days ago | |
Semaglutide removed from FDA drug shortage list by June 30, 2024? | Binary | | | 4 days ago | |
Will Apple's market cap exceed $4 trillion by March 31, 2025? | Binary | | | 4 days ago | |
Will Apple's P/E ratio drop below 35 by June 30, 2025? | Binary | | | 4 days ago | |
Will Apple announce a stock split by the end of 2025? | Binary | | | 4 days ago | |
Will RFK Jr. revoke polio vaccine approval in the US by end of 2025? | Binary | | | 7 days ago | |
Will Trump publicly oppose the polio vaccine by end of 2025? | Binary | | | 7 days ago | |
Most prescribed diabetes drug in Europe by end of 2025? | Categorical | | | 9 days ago | |
Will FDA issue warning or ban on compounded GLP-1 drugs by end of 2025? | Binary | | | 12 days ago | |
Will Zepbound price drop by 20% or more by June 30, 2025? | Binary | | | 12 days ago | |
Will the FDA approve Zepbound for an expanded indication by end of 2025? | Binary | | | 19 days ago | |
Will Novo Nordisk announce a new clinical trial to compete with Zepbound by June 2025? | Binary | | | 19 days ago | |
Will fluoride be removed from US drinking water by end of 2025? | Binary | | | 1 month ago | |
Will the US mandate cane sugar in Coca-Cola by end of 2025? | Binary | | | 1 month ago | |
Will tirzepatide be FDA approved for HFpEF by end of 2025? | Binary | | | 1 month ago | |
Will tirzepatide be included in AHA HFpEF guidelines by end of 2025? | Binary | | | 1 month ago | |